Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A6LB
|
||||
| Former ID |
DNC010256
|
||||
| Drug Name |
2-(piperazin-1-yl)-5,6,7,8-tetrahydroquinoline
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [530516] | ||
| Formula |
C13H19N3
|
||||
| Canonical SMILES |
C1CCC2=C(C1)C=CC(=N2)N3CCNCC3
|
||||
| InChI |
1S/C13H19N3/c1-2-4-12-11(3-1)5-6-13(15-12)16-9-7-14-8-10-16/h5-6,14H,1-4,7-10H2
|
||||
| InChIKey |
OHJFBSROVXQKFQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Inhibitor | [530516] | |
| 5-hydroxytryptamine 2A receptor | Target Info | Inhibitor | [530516] | ||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||